Related Experiment Video
Updated: Jan 17, 2026
A Preclinical Mouse Model of Osteosarcoma to Define the Extracellular Vesicle-mediated Communication Between Tumor and Mesenchymal Stem Cells
Published on: May 6, 2018
Targeting the hsa_circ_0000253/miR-7/COL5A2 Axis: Unveiling CCT-018159's Role in Halting Osteosarcoma Progression
Xu Guo1, Xiangrui Zhu1,2, Xin Tian1
1School of Chemical Engineering, Ocean Technology and Life Science, Dalian University of Technology, Panjin, China.
Abstract:
Osteosarcoma (OS) is the most common malignant bone tumor in children and adolescents, marked by aggressive local invasion and early metastasis. This study investigated the regulatory role of the hsa_circ_0000253/miR-7/COL5A2 axis and the therapeutic potential of CCT-018159 in OS progression. Differential expression and ceRNA network analyses identified hsa_circ_0000253 as a key regulator. Functional experiments demonstrated that silencing hsa_circ_0000253 or COL5A2 suppressed OS cell proliferation and migration, whereas inhibition of miR-7 enhanced these processes. Single-cell transcriptomics revealed distinct OS cell subclusters, with high-risk cells characterized by elevated expression of COL5A2, IGF1R, COL1A1, and COL1A2, indicating progression toward aggressive phenotypes. Molecular docking further identified CCT-018159 as a candidate drug capable of markedly reducing OS cell proliferation and migration. These findings highlight the hsa_circ_0000253/miR-7/COL5A2 axis as a critical driver of OS malignancy and suggest CCT-018159 as a promising therapeutic agent, warranting further in vivo validation and clinical exploration.
Insights
This study reveals the hsa_circ_0000253/miR-7/COL5A2 pathway drives osteosarcoma (OS) progression. The drug candidate CCT-018159 shows potential for treating this common childhood bone cancer.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Osteosarcoma (OS) is a prevalent pediatric bone cancer with aggressive characteristics.
- Understanding the molecular mechanisms driving OS progression is crucial for developing effective therapies.
Purpose of the Study:
- To investigate the regulatory role of the hsa_circ_0000253/miR-7/COL5A2 axis in OS.
- To evaluate the therapeutic potential of CCT-018159 in OS.
Main Methods:
- Differential expression analysis and ceRNA network construction.
- Functional experiments (gene silencing/inhibition) and single-cell transcriptomics.
- Molecular docking simulations.
Main Results:
- hsa_circ_0000253 acts as a key regulator in OS.
- Silencing hsa_circ_0000253 or COL5A2 inhibits OS cell proliferation and migration.
- Inhibiting miR-7 enhances OS cell proliferation and migration.
- High-risk OS cells show elevated COL5A2 and collagen gene expression.
- CCT-018159 significantly reduces OS cell proliferation and migration in silico.
Conclusions:
- The hsa_circ_0000253/miR-7/COL5A2 axis is a critical driver of osteosarcoma malignancy.
- CCT-018159 demonstrates promise as a therapeutic agent for osteosarcoma.
- Further in vivo and clinical studies are warranted for CCT-018159.
Related Concept Videos
02:07Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
03:03mTOR Signaling and Cancer Progression
The mTOR pathway or the...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...